Javascript must be enabled to continue!
Malignancy and Immune Disorders in Patients With Hereditary Angioedema
View through CrossRef
Abstract
Background
With the advent of new therapies, patients with hereditary angioedema (HAE) are living longer lives. Although complement dysregulation has been linked to various disease states, it is currently not known if HAE patients are at an increased risk of developing malignancy or autoimmune conditions.
Case Presentation
: We reviewed the charts of 49 HAE patients and identified 6 patients who had a co-existing malignancy diagnosis (two with breast cancer, one with melanoma, one with pancreatic cancer, one with renal cancer and one with cervical dysplasia) and 6 patients who had a diagnosis of a co-existing immune disorder (two with rheumatoid arthritis, two with ulcerative colitis, one with chronic urticaria with hypothyroidism and one with Sjogren’s syndrome). Nearly all malignancy cases occurred in older HAE patients (> 50 years) and malignancy was diagnosed before HAE in 3 of the patients.
Conclusions
Our case series has identified multiple hereditary angioedema (HAE) patients with co-existing malignancy and immune disorders. Based on these findings, we would advocate that physicians managing HAE patients should maintain a high index of suspicion for these conditions.
Title: Malignancy and Immune Disorders in Patients With Hereditary Angioedema
Description:
Abstract
Background
With the advent of new therapies, patients with hereditary angioedema (HAE) are living longer lives.
Although complement dysregulation has been linked to various disease states, it is currently not known if HAE patients are at an increased risk of developing malignancy or autoimmune conditions.
Case Presentation
: We reviewed the charts of 49 HAE patients and identified 6 patients who had a co-existing malignancy diagnosis (two with breast cancer, one with melanoma, one with pancreatic cancer, one with renal cancer and one with cervical dysplasia) and 6 patients who had a diagnosis of a co-existing immune disorder (two with rheumatoid arthritis, two with ulcerative colitis, one with chronic urticaria with hypothyroidism and one with Sjogren’s syndrome).
Nearly all malignancy cases occurred in older HAE patients (> 50 years) and malignancy was diagnosed before HAE in 3 of the patients.
Conclusions
Our case series has identified multiple hereditary angioedema (HAE) patients with co-existing malignancy and immune disorders.
Based on these findings, we would advocate that physicians managing HAE patients should maintain a high index of suspicion for these conditions.
Related Results
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review
Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review
Angioedema is a health issue that affects parts of the body like the upper pulmonary
and gastric pathways and is identified by abrupt, nonpitting enlargement of the skin, mucous me...
Clinical Implications of Cytopenias in the U.S. Immunodeficiency Network Registry
Clinical Implications of Cytopenias in the U.S. Immunodeficiency Network Registry
Rationale
The correlation between cytopenias and infection, malignancy, and mortality has not been systematically characterized in patients with inborn errors of ...
EPD Electronic Pathogen Detection v1
EPD Electronic Pathogen Detection v1
Electronic pathogen detection (EPD) is a non - invasive, rapid, affordable, point- of- care test, for Covid 19 resulting from infection with SARS-CoV-2 virus. EPD scanning techno...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Exploring metabolic dysregulation and therapeutic targets in sickle cell disease and rare hereditary red blood cell disorders
Exploring metabolic dysregulation and therapeutic targets in sickle cell disease and rare hereditary red blood cell disorders
Hereditary red blood cell (RBC) disorders are genetically and phenotypically heterogenous disorders that may all impact RBC metabolism to a variable extent. Hereditary hemolytic an...
Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma
Defining heterogeneity in the immune infiltrate of gastroesophageal adenocarcinoma
Gastro-esophageal adenocarcinoma (GEAC) is a cancer with a poor prognosis and limited treatment options. Most patients present with metastatic disease, where systemic therapies off...
Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules
Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules
AbstractObjective Controversy surrounds the evaluation of nodules with indeterminate cytology results. Malignancy rates in these nodules are not low. We examined the malignancy rat...

